Dr. Michael Mingueneau, PhD

Head of Immunology at Sail Biomedicines

Speaker

Dr. Mingueneau is Head of Immunology at Sail Biomedicines, where his current responsibilities include building out the company's immunology unit and pipeline as well as defining a vision and strategy to transform the care of patients with immunological diseases with innovative RNA programmable medicines. Dr. Mingueneau is an immunologist and drug discovery leader experienced with target identification/validation and successful advancement of programs from early preclinical stage towards R2D transition and IND/phase 1 in the fields of peripheral autoimmunity, neuroinflammation and immuno-oncology. He joined Sail from Biogen, where he held positions of increasing responsibility in the Multiple Sclerosis, Neuroimmunology and Immunology franchises over a period of ten years. At Biogen, Dr. Mingueneau led advancement of several antibody and small molecule programs including BIIB091 BTK inhibitor currently in phase 2 trial in Multiple Sclerosis patients. Before Biogen, Michael Mingueneau completed his postdoctoral training in the laboratories of Drs. C. Benoist and D. Mathis (Harvard Medical School, Boston, US) following a Ph.D. in Immunology with Drs. B. and M. Malissen (CIML & Aix-Marseille University, France).